Q4 2024 Earnings Call Transcript February 18, 2025 Axsome Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

Harmony Biosciences' ( NASDAQ: HRMY) stock fell about 7.3% after U.S. FDA notified the company that it will not review the ...

Harmony Biosciences currently markets pitolisant as WAKIX® in the U.S. for the treatment of EDS or cataplexy in adult patients with narcolepsy and for EDS in pediatric patients 6 years of age and ...

Harmony Sciences shares plunged Wednesday after the FDA rejected its bread-and-butter drug as a treatment for a daytime sleepiness condition.

Total 4Q and full year 2024 net product revenue of $118.8 million and $385.7 million, respectively, representing 66% and 88% year-over-year ...

Nations Financial Group Inc. IA ADV acquired a new position in Avadel Pharmaceuticals plc (NASDAQ:AVDL – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & ...

Avadel Pharmaceuticals plc (NASDAQ:AVDL – Get Free Report) was the target of a large decrease in short interest in January. As of January 31st, there was short interest totalling 10,550,000 shares, a ...

Axsome Therapeutics reports 66% Q4 revenue growth, blockbuster potential for Auvelity, and robust pipeline progress with 3 NDA filings and key ...

An expert discusses treatments for narcolepsy, comparing options for managing excessive daytime sleepiness (EDS) and cataplexy, and examines the advantages, limitations, and clinical scenarios for ...

AXSM's fourth-quarter 2024 earnings miss estimates while revenues beat the same. Net product sales rise year over year.

"Drivers must understand the nature of not disclosing medical conditions to the DVLA. Beyond the risk of fines, failure to ...